Ameren options swing bullish as shorts hold near year highs

Options traders moved sharply toward calls on Ameren Corporation on Tuesday, even as short interest sits at its highest level in at least a year. The put/call ratio fell to 0.27, the lowest in 52 weeks and two standard deviations below the 20-day mean of 0.45. That divergence between a growing short book and a call-heavy options market is the tension worth tracking into the November 5 earnings date.

Shorts at a year high, but the borrow market is calm

Short interest stands at 5.6% of the free float as of October 19, up 22% over the past month. The month-long build is the standout number. From the start of October alone, shares short climbed from roughly 12 million to 15.2 million, a clear directional move for a regulated utility whose earnings are set largely by rate cases rather than economic cycles.

The cost to borrow has risen in tandem, up more than 80% over the past week to 0.46%. In absolute terms that remains low. Availability is 1,059%, meaning roughly ten shares are available to lend for every one already borrowed. There is no supply squeeze here. The rising cost reflects increased demand, not a shrinking pool. Shorts are paying more because more of them want the position, not because the borrow is running dry.

The ORTEX short score has also moved. It climbed from 46.7 on October 6 to 51.2 on October 19, its highest reading in the window shown.

Calls dominate as the PCR hits a 52-week low

The options picture points the other way. The PCR of 0.27 is near the bottom of its 52-week range of 0.05 to 0.92. The 20-day average sits at 0.45. A reading two standard deviations below that average is not routine positioning noise. Options traders are expressing a view that the stock moves higher or at least does not fall.

Ameren is up 1.8% over the past week, slightly ahead of the median for its closest peers: WEC gained 2.0%, CMS 2.3%, CNP 1.4%. The modest outperformance has come alongside a run of analyst target cuts. BMO Capital lowered its target from $119 to $113 on October 20, maintaining Outperform. Barclays cut from $117 to $109, keeping Equal-Weight. Truist trimmed from $120 to $116, keeping Buy. Keybanc moved in the other direction, raising its target from $116 to $122. The mean consensus target stands at $114.94 against a current price of $106.23.

The EPA's own data adds a footnote

One figure from Ameren's own operational record is worth noting. EPA Clean Air Markets Program data shows June 2026 was the smallest June for gross capacity factor by operator on record since 2024. That data covers Ameren's generation fleet and reflects output, not revenue. The nuclear reactor output signal registered a z-score of minus 4.8 as of October 7, a sharp negative deviation from the unit's own trailing history. The nuclear dataset is untested against Ameren's financials, so no revenue inference should be drawn from it.

Watch the November 5 earnings date. That is the next hard catalyst. Short interest at a year high alongside the most call-skewed options positioning in 52 weeks means the two sides of the market are not reading the same script.